All treatments
Treatment
Valemetostat Tosylate clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial of Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in Participants with Advanced or Metastatic Non-small Cell Lung Cancer whose Tumors Express PD-L1 with Tumor Proportion Score ≥50% Without Actionable Genomic Alterations
This study looks at a new drug, Valemetostat Tosylate, combined with Pembrolizumab (Keytruda) for advanced lung cancer. It compares this combination to Keytruda alone in people whose cancer has a specific marker and hasn't spread to other parts of the body.
For: Advanced or Metastatic Non-Small Cell Lung CancerSpain · France · Italy - Active not recruitingPHASE2
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
This study looks at a new medicine called Valemetostat Tosylate for people with certain types of T-cell lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective the medicine is.
For: Relapsed/Refractory Peripheral T-Cell Lymphoma · Adult T Cell Leukemia/LymphomaUnited States · Australia · Canada